**Core Concept**
The underlying principle being tested is the management of secondary amenorrhea due to hyperprolactinemia. **Hyperprolactinemia** is characterized by elevated serum **prolactin** levels, which can disrupt the normal menstrual cycle.

**Why the Correct Answer is Right**
Since the correct answer is not provided, I will explain the general approach to treating secondary amenorrhea with hyperprolactinemia. The treatment typically involves **dopamine agonists**, which inhibit **prolactin** secretion from the **pituitary gland**.

**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific option, it's challenging to provide a detailed explanation. However, if it's not a **dopamine agonist**, it's likely incorrect.
**Option B:** Similarly, without the option, it's difficult to assess its accuracy.
**Option C:** If this option is not related to reducing **prolactin** levels, it's incorrect.
**Option D:** If it's not a standard treatment for hyperprolactinemia, it's wrong.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that **cabergoline** and **bromocriptine** are common **dopamine agonists** used to treat hyperprolactinemia.

**Correct Answer:**